American Oriental Bioengineering, Inc. (AOBI)
- Previous Close
0.0005 - Open
0.0005 - Bid --
- Ask --
- Day's Range
0.0005 - 0.0005 - 52 Week Range
0.0003 - 0.0005 - Volume
11 - Avg. Volume
0 - Market Cap (intraday)
72,991 - Beta (5Y Monthly) 6.21
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3700 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
American Oriental Bioengineering, Inc. engages in the development, manufacture, and commercialization of various pharmaceutical and healthcare products. The company primarily provides prescription pharmaceutical products, including Shuanghuanglian Lyophilized Injection Powder under the SHL brand for the treatment of flu symptoms, such as high fever, cough, and sore throat, as well as upper respiratory infections, mild pneumonia, bronchitis, and tonsillitis; and Cease Enuresis Soft Gel under the CE Gel brand to alleviate bedwetting. It also offers over-the-counter pharmaceutical products comprising Cease Enuresis Patch for the treatment of bedwetting and incontinence; Jinji Capsule for the treatment of endometritis, annexitis, and pelvic inflammations; Jinji Yimucao for the treatment of premenstrual syndrome (PMS) and other PMS and menopause-related symptoms; and Boke Nasal Spray for the treatment of sinus congestion from common cold, stuffy nose, chronic rhinitis, allergic rhinitis, and nasosinusitis. In addition, the company provides various nutraceutical products, such as soybean peptide based drinks, tablets, powder, and instant coffee. Further, it is involved in the wholesale and retail of pharmaceutical and nutraceutical products. The company sells its products directly and through distributors to hospitals, clinics, pharmacies, supermarkets, fitness centers, specialty nutraceutical stores, and other retail outlets in the People's Republic of China. American Oriental Bioengineering, Inc. is headquartered in Beijing, China.
Related News
Performance Overview: AOBI
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AOBI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AOBI
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
0.74
Enterprise Value/EBITDA
-3.10
Financial Highlights
Profitability and Income Statement
Profit Margin
-74.86%
Return on Assets (ttm)
-6.30%
Return on Equity (ttm)
-28.22%
Revenue (ttm)
121.58M
Net Income Avi to Common (ttm)
-91.02M
Diluted EPS (ttm)
-0.3700
Balance Sheet and Cash Flow
Total Cash (mrq)
3.23M
Total Debt/Equity (mrq)
32.70%
Levered Free Cash Flow (ttm)
-27.25M